The China Regulatory Commission said in a statement late on Sunday that it would strengthen its supervision of IPOs, after a small drug maker postponed its share sale saying it was "too big".
The stock watchdog, which had promised a more hands-off approach to IPOs after resuming them earlier this month following a 15-month hiatus, said it will step up monitoring of the deals and their pricing.
The statement comes after Jiangsu Aosaikang Pharmaceutical said on Friday it had delayed its IPO after pricing it at 72.99 yuan per share, equivalent to 67 times its 2012 net profit.
(Read more: End of China's IPO freeze really bad news for stocks?)
The average PE ratio of pharmaceutical companies listed on Shenzhen's Nasdaq-style ChiNext is 55.31, according to the state-run Shanghai Securities Journal.
The CSRC denied it had forced Jiangsu Aosaikang Pharmaceutical to halt its IPO, saying the decision was made by the company and the underwriter, China International Capital. But sources familiar with the matter had earlier told Thomson Reuters publication IFR that the regulator had pressured the drug maker to postpone.